PUBLIC HEALTH PRACTICE
NEXT Harm Reduction: An Online, MailBased Naloxone Distribution and Harm-Reduction Program Carol Yang, BA, Jamie Favaro, MSW, and Meredith C. Meacham, PhD, MPH
Needle EXchange Technology (NEXT) Harm Reduction is an online, mail-based platform designed for sending (1) naloxone kits to people at risk for overdose and (2) sterile syringes and other equipment directly to people who otherwise cannot access safe supplies. From its inception in 2017 through the end of 2019, NEXT Harm Reduction sent naloxone kits to 3609 individuals and 1230 packages of sterile syringes and supplies and received 335 reports of overdose reversals using naloxone provided by NEXT Harm Reduction and its affiliates. (Am J Public Health. Published online ahead of print February 18, 2021: e1–e5.
overdose, and NEXT Distro, which mails
implementation, impact, and public
sterile syringes and other drug use
PERSON
health significance of Needle EXchange
equipment, as well as naloxone, directly
NEXT targets people who use drugs and
Technology (NEXT) Harm Reduction and
to people who otherwise cannot access
their loved ones who are not able to
outline challenges and opportunities to
safe supplies. Both programs are ac-
access naloxone or sterile syringes and
inform other organizations who may be
cessible via https://nextdistro.org.
other resources for safer drug use in
interested in expanding or integrating
(Before October 2020, NEXT Nalox-
their local communities.
online, mail-based harm-reduction ser-
one’s Web page was https://www.
vices in their communities.
naloxoneforall.org, which now redirects
PURPOSE
to https://nextdistro.org.)
INTERVENTION
Many people in the United States still
PLACE AND TIME
have little or no access to naloxone (brand name: Narcan), the Food and
NEXT Harm Reduction is an online, mailbased platform designed to reduce
Through a network of harm-reduction
Drug Administration–approved medica-
opioid overdose deaths; prevent
agencies and health departments, NEXT
tion that prevents opioid overdose death
injection-related transmission of condi-
serves participants in all 50 states;
by reversing opioid-induced respiratory
tions including HIV, hepatitis C, and soft
Washington, District of Columbia; and
depression.2 Furthermore, people who
tissue bacterial infections; and improve
Puerto Rico. It is based in New York City,
use drugs still face physical, legal, and
the lives of people who use drugs and
where it is a registered New York State
societal barriers to supplies for safer drug
1
Published online ahead of print February 18, 2021
I
n this article, we describe the purpose,
AJPH
https://doi.org/10.2105/AJPH.2020.306124)
their loved ones. It is a 501(c)(3) orga-
Opioid Overdose Prevention Program
use. Stigma against and criminalization of
nization originally sponsored by the
and Syringe Exchange Program. NEXT
drug use continues to prevent many
Harm Reduction Coalition.
Distro began services in February 2018
people from accessing lifesaving re-
NEXT Harm Reduction runs two pro-
and NEXT Naloxone began services in No-
sources even when they are available.3 As
grams: NEXT Naloxone, which provides
vember 2018. It was inspired by the work of
smartphone and Internet use becomes
online overdose prevention education
Tracey Helton and conversations at the
more accessible, people are increasingly
and mail-delivered naloxone kits to
2016 National Harm Reduction Coalition
using the Internet to obtain health infor-
the loved ones of people at risk for
Conference in San Diego, California.
mation, medications, and supplies.4
Public Health Practice
Peer Reviewed
Yang et al.
e1
PUBLIC HEALTH PRACTICE
IMPLEMENTATION
TABLE 1—
Demographics and Overdose Experiences of NEXT Naloxone Requesters: United States and Puerto Rico: November 2018–December 2019
Program participants typically learn about NEXT Naloxone through social media (48%) and personal connections (23%; Table 1). This information was not
Age, y
systematically collected from NEXT Dis-
< 26
tro participants to reduce program and
26–45
2352 (60)
participant burden.
46–65
677 (17)
Along with mailing supplies, NEXT programs include a handwritten note
> 65
43 (1)
Gender identitya Male
1334 (34)
package. Web pages and other written
Female
2390 (61)
materials are offered in English and
Gender nonconforming or nonbinary
referrals to other support services in their area, including buprenorphine Published online ahead of print February 18, 2021
848 (22)
and informational materials in each
Spanish. Participants can also request
AJPH
New Requests, No. (%)
providers, harm reduction–oriented physicians, and mental health services. Postage for NEXT is paid for through grant funding and donations. NEXT sends packages through the US Postal Service priority mail, which typically take two to four days to arrive to participants.
Transgender
141 (4) 43 (1)
Racial/ethnic identitya White or Caucasian
3448 (88)
Black or African American
119 (3)
Hispanic or Latinx
278 (7)
Asian
104 (3)
American Indian or Alaska Native
67 (2)
Native Hawaiian or Pacific Islander
24 (1)
Overdose experience in past year Witnessed
2162 (55)
Has overdosed
344 (9) b
Region: Northeast
NEXT Naloxone
Total requests
771 (20)
Filled (% of total)
672 (87)
Diverted to local programs (% of total)
53 (7)
Region: Midwestc
Upon arriving on the NEXT Naloxone
Total requests
1132 (29)
Web page, participants select which
Filled (% of total)
1046 (92)
state they reside in and are directed to a
Diverted to local programs (% of total)
state-specific resource page. If they are
34 (3)
d
Region: South and Puerto Rico
unable to access resources in their state,
Total requests
1349 (34)
participants can watch a training video
Filled (% of total)
1262 (94)
on overdose recognition and naloxone use, then fill out a secure online form to
Diverted to local programs (% of total)
31 (2)
Region: Weste
request naloxone via mail. In states
Total requests
674 (17)
where NEXT Naloxone has a partner
Filled (% of total)
629 (93)
affiliate (typically a local harm-reduction
Diverted to local programs (% of total)
organization that already distributes
31 (5) Continued
naloxone within their state), NEXT forwards the request to the affiliate to coordinate and fulfill the delivery. Part-
expected turnaround times for requests
intranasal Narcan-brand naloxone.
ner affiliates have signed memoranda of
to be mailed out.
The type and amount of naloxone sent
understanding with NEXT, which include terms of participant confidentiality and e2
Public Health Practice
Peer Reviewed
Yang et al.
NEXT offers both intramuscular naloxone vials with syringes and
to each participant depends on their request, level of overdose risk, state of
PUBLIC HEALTH PRACTICE
TABLE 1—
residence, and available inventory Continued
(typically two to four doses, or more New Requests, No. (%)
How requester heard about NEXT Naloxone Social media
for individuals at higher risk for overdose).
f
1889 (48)
Personal connection
910 (23)
Online search or Web site
680 (17)
Recovery or support group
178 (5)
NEXT Distro To access NEXT Distro services, people connect via the program Web site
Note. The sample size was 3926.
(https://nextdistro.org) or reach out di-
a
rectly via e-mail, text message, or social media (Instagram: @nextdistro; Reddit: u/nextdistro). NEXT Distro then sends participants a link to the enrollment request form. Depending on what participants request, packages mailed to them contain supplies typically available at in-person harm-reduction programs: packs of syringes available in multiple and cotton, and safer smoking, safer sex, and wound care supplies.
TABLE 2—
Naloxone Use Reports to NEXT Harm Reduction: United States and Puerto Rico, November 2018–December 2019 a
Naloxone Use Reports, No. (%)
EVALUATION From November 2018 through December 2019, NEXT Naloxone received 3926 new requests via https://www.
Did the person who overdosed survive? Yes
335 (95)
naloxoneforall.org (Table 1). Of these,
No
9 (3)
3609 (92%) were filled by NEXT Nalox-
Not sure
9 (3)
one (1812 directly, 1797 via affiliates),
Relationship of person who reported overdose to person who overdosed Friend or acquaintance Family member or partner Patient or client
149 (4%) were diverted to local programs, and 168 (4%) were undeliver-
161 (46)
able. From February 2018 to
84 (24)
December 2019, NEXT Distro sent
6 (2)
Stranger
72 (20)
Unknown or prefer not to answer
30 (8)
1230 packages containing syringes and other supplies. Each naloxone kit and package in-
Location of overdose Home or apartment
cludes reminders with the link to an
238 (67)
Public - inside
21 (6)
online form for participants to report
Public - outside
58 (16)
back to the program if they have used
4 (1)
the naloxone from NEXT to respond to
32 (9)
an overdose and whether the reversal
Shelter or supportive housing Other or unknown
Published online ahead of print February 18, 2021
sizes, hazardous material bins, cookers
AJPH
People could select more than one response option for racial/ethnic and gender identity. b Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. c Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. d South and Puerto Rico: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, Puerto Rico, South Carolina, Tennessee, Texas, Virginia, and West Virginia. e West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. f Based on free text responses to the question “How did you hear about NEXT Naloxone?”; response categories are not mutually exclusive (e.g., “Facebook friend” would count as social media and personal connection).
attempt of the overdose was suc-
Region Northeastb c
Midwest
cessful. NEXT also e-mails periodic
62 (18)
reminders to all participants who have
63 (18) Continued
received kits to report back to the
Public Health Practice
Peer Reviewed
Yang et al.
e3
PUBLIC HEALTH PRACTICE
TABLE 2—
communities of color at higher risk of Continued
experiencing or witnessing an overdose.7 Naloxone Use Reports,a No. (%)
d
South and Puerto Rico
188 (53)
Weste Demographics of person who overdosed
While NEXT has not received reports
Age, y
of adverse effects or unintended con-
< 26
91 (26)
26–45
216 (61)
46–65
21 (6)
> 65
0 (0)
Unknown
25 (7)
Gender identity
Published online ahead of print February 18, 2021
ADVERSE EFFECTS
40 (11)
Male
227 (64)
Female
100 (28)
Gender nonconforming or nonbinary
2 (1)
Transgender
3 (1)
Not reported
21 (6)
sequences, a primary concern is the confidentiality of participant information related to admission of substance use or interception of packages. To guard against this, NEXT does not connect participant enrollment data (i.e., names, addresses) with potentially sensitive substance use information. The processes of enrolling and requesting supplies are separated and connected through a participant-
Racial/ethnic Identity White or Caucasian
262 (74)
chosen “handle.” Furthermore, NEXT
Black or African American
32 (9)
encourages participants to use
Hispanic or Latinx
21 (6)
encrypted messaging applications to
Asian
5 (1)
communicate with the program. Nev-
American Indian or Alaska Native
8 (2)
ertheless, many program participants
Native Hawaiian or Pacific Islander
0 (0)
report more concern about scarcity of syringes and naloxone than about po-
Previously experienced overdose 188 (53)
No or not sure
165 (47)
AJPH
Yes
tential privacy risks.
SUSTAINABILITY
Note. The sample size was 353. a
Some people reported multiple naloxone use reports. Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. c Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. d South and Puerto Rico: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, Puerto Rico, South Carolina, Tennessee, Texas, Virginia, and West Virginia. e West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. b
The sustainability of NEXT is largely driven by affiliate partnerships based in communities where participants are requesting supplies. Affiliate partners are able to tailor delivery of supplies to local circumstances and can develop more direct supportive relationships with participants.
program if they use their naloxone and
e4
A central limitation and concern of
One concern of expansion via govern-
may need refills. During this period,
NEXT is that it is primarily reaching in-
ment partnerships is whether formaliza-
there were 353 participant reports of
dividuals who have a dependable mail-
tion will create barriers that prevent
naloxone used to respond to an over-
ing address and reliable access to the
participants from electing to share their
dose, of which 335 (95%) were successful
Internet, creating barriers for participants
information. Government partners
in reviving the person overdosing
who are unhoused, unstably housed, or
should be aware of this concern and
(Table 2). This is likely an underestimate as
without Internet access.6 Furthermore, as
ensure that identifying participant infor-
lay person overdose reversals are often
program participant demographic data
mation is not used or distributed for any
underreported.5
show, NEXT has had limited reach in
purpose beyond provision of supplies.
Public Health Practice
Peer Reviewed
Yang et al.
PUBLIC HEALTH PRACTICE
PUBLIC HEALTH SIGNIFICANCE
Note. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
In the context of the opioid overdose
CONFLICTS OF INTEREST
crisis and ongoing HIV and hepatitis C
The authors have no conflicts of interest to declare.
epidemics, as well as active political opposition to local syringe access programs in many parts of the country, NEXT Harm Reduction provides an innovative platform for people who use drugs and others in their community to connect with low-barrier access to information, support, and life-saving medication and supplies. ABOUT THE AUTHORS
Correspondence should be sent to Meredith Meacham, 401 Parnassus Ave, San Francisco, CA 94143 (e-mail: meredith.meacham@ucsf.edu). Reprints can be ordered at http://www.ajph.org by clicking the “Reprints” link.
PUBLICATION INFORMATION Full Citation: Yang C, Favaro J, Meacham MC. NEXT harm reduction: an online, mail-based naloxone distribution and harm-reduction program. Am J Public Health. Published online ahead of print February 18, 2021: e1–e5. Acceptance Date: December 13, 2020. DOI: https://doi.org/10.2105/AJPH.2020.306124
CONTRIBUTORS C. Yang is the former program director for NEXT Harm Reduction and contributed to the writing and editing of the article. J. Favaro is the founder and executive director of NEXT Harm Reduction and contributed to the editing of the article. M. Meacham performed the data analyses and contributed to the writing and editing of the article.
REFERENCES 1. Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–e1220. https://doi. org/10.1016/S2214-109X(17)30373-X 2. Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172–179. https://doi.org/10.1016/j.drugpo. 2017.06.005
Published online ahead of print February 18, 2021
CORRESPONDENCE
Institutional review board approval was not required for this study because the data were collected for program evaluation purposes and presented in aggregate.
AJPH
Carol Yang and Jamie Favaro are with NEXT Harm Reduction, New York, NY. Meredith Meacham is with the Department of Psychiatry and Behavioral Sciences at the University of California San Francisco.
HUMAN PARTICIPANT PROTECTION
3. Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11): e1002969. https://doi.org/10.1371/journal.pmed. 1002969 4. Greenberg-Worisek AJ, Kurani S, Finney Rutten LJ, Blake KD, Moser RP, Hesse BW. Tracking Healthy People 2020 Internet, broadband, and mobile device access goals: an update using data from the Health Information National Trends Survey. J Med Internet Res. 2019;21(6):e13300. https://doi.org/10. 2196/13300 5. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631–635. 6. van Draanen J, Tsang C, Mitra S, Karamouzian M, Richardson L. Socioeconomic marginalization and opioid-related overdose: a systematic review. Drug Alcohol Depend. 2020;214:108127. https://doi.org/ 10.1016/j.drugalcdep.2020.108127 7. Lippold KM, Jones CM, Olsen EO, Giroir BP. Racial/ ethnic and age group differences in opioid and synthetic opioid–involved overdose deaths among adults aged ≥18 years in metropolitan areas— United States, 2015–2017. MMWR Morb Mortal Wkly Rep. 2019;68(43):967–973. https://doi.org/10. 15585/mmwr.mm6843a3
ACKNOWLEDGMENTS Manuscript development was supported by National Institutes of Health grant K01DA046697. The authors would like to acknowledge Tracey Helton for her pioneering work in mail-based naloxone distribution, Dan Coello for their data management assistance, and advisors and affiliates of NEXT Harm Reduction.
Public Health Practice
Peer Reviewed
Yang et al.
e5